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Abstract
Background: A variety of study designs are available to evaluate the accuracy of tests, but the terms used to
describe these designs seem to lack clarity and standardization. We investigated if this was the case in the
diagnostic guidance of the National Institute of Care and Health Excellence (NICE), an influential source of advice
on the value of tests.
Objectives: To describe the range of study design terms and labels used to distinguish study designs in NICE
Diagnostic Guidance and the underlying evidence reports.
Methods: We carefully examined all NICE Diagnostic Guidance that has been developed from inception in 2011
until 2018 and the corresponding diagnostic assessment reports that summarized the evidence, focusing on
guidance where tests were considered for diagnosis. We abstracted labels used to describe study designs and
investigated what labels were used when studies were weighted differently because of their design (in terms of
validity of evidence), in relevant sections. We made a descriptive analysis to assess the range of labels and also
categorized labels by design features.
Results: From a total of 36 pieces of guidance, 20 (56%) were eligible and 17 (47%) were included in our analysis.
We identified 53 unique design labels, of which 19 (36%) were specific to diagnostic test accuracy designs. These
referred to a total of 12 study design features. Labels were used in assigning different weights to studies in seven
of the reports (41%) but never in the guidance documents.
Conclusion: Our study confirms a lack of clarity and standardization of test accuracy study design terms. There
seems to be scope to reduce and harmonize the number of terms and still capture the design features that were
deemed influential by those compiling the evidence reports. This should help decision makers in quickly identifying
subgroups of included studies that should be weighted differently because their designs are more susceptible to
bias.
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Introduction
Critical appraisal of studies is an essential element of
evidence-based medicine. A first step in an evaluation is
to identify the type of studies used to generate the evi-
dence. Depending on the design used, the validity may
be threatened. Some study designs are more likely than
others to generate evidence that is free from systematic
errors, i.e. bias.
The selection, recruitment and flow of participants—
hence, the study design—is one of the most important
pieces of information needed to assess validity in diag-
nostic test accuracy (DTA) studies. However, DTA study
designs and their intrinsic biases differ from those of,
say, drug trials. The validity of a DTA study depends in
particular on how and where participants were recruited
and, among other features, whether the complete study
group or subgroups underwent both the index test and
reference standard. In DTA studies, ideally, a single,
consecutive group of participants undergoes both the
index test and the reference standard. Meta-
epidemiological studies have convincingly shown that
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some types of study design lead to biased estimates of
the performance of diagnostic tests [1–3].
A clear description of the crucial design features of
DTA studies, preferably with a concise label, may help in
characterizing a study. In comparative studies of the ef-
fectiveness of interventions, for example, randomized
clinical trials offer stronger evidence than studies with-
out randomization, since randomization of a large group
of participants reduces bias due to confounding. As
such, the ability to distinguish randomized from non-
randomized studies is crucial for the evaluation of any
study [4]. Likewise, in etiological questions, labels from
epidemiology, such as “case-control study” and “cohort
study”, provide crisp and clear information of how the
identification of study participants was organized [5].
Unfortunately, to our knowledge, there is no set of
comparable standardized labels or terms for describing
diagnostic accuracy study designs. This absence may
generate confusion.
In systematic reviews of DTA studies, the QUADAS-2
instrument is the most often used tool to evaluate the
risk of bias and to identify concerns about the applicabil-
ity of findings of DTA studies [6] and the STARD check-
list encourage clear and transparent reporting [7].
However, none of these tools offers standardized termin-
ology for describing the study designs. Moreover, the
QUADAS-2 uses the case-control terminology in the
item that evaluates patient selection (the risk of
spectrum bias). Consequently, any confusion arising
from this is not limited to readers of the primary studies.
It also has potential implications for the assessment of
bias and applicability of studies included in the evidence
synthesis that informs clinical guidelines and health
policies.
The National Institute for Care and Health Excellence
(NICE) is well recognized for developing evidence-based
clinical guidelines. Since 2011, the NICE Diagnostic As-
sessment Programme (DAP) has developed specific diag-
nostic guidance. DAP was among the first international
bodies to develop guidelines and to offer guidance for
DTA evidence synthesis. Although the programme fol-
lows high international standards for evidence synthesis,
the terminology and labels used to describe the evidence
varies and includes labels non-specific to DTA (e.g. “pro-
spective cohort or cross-sectional studies, or retrospect-
ive case-control studies”) [8]. Hence, without the ability
to clearly communicate different threats, there is a risk
that guidance committees may miss important aspects
and implications of study designs.
We investigated the use of study design labels to de-
scribe test accuracy studies in the development of NICE
diagnostic guidance. We extracted data to describe the
range of study design terms and labels in the NICE
evidence reports of diagnostic accuracy reviews and
guidance documents and to investigate what labels were
used when studies were weighted differently because of
their design.
Methods
Guidance identification and eligibility criteria
A NICE diagnostic guidance is developed in several
steps. In short, an external academic assessment group
performs a systematic review of the evidence (i.e. the
diagnostic assessment report, DAR), for a given question
issued by NICE. The report is evaluated by the NICE
Diagnostics Advisory Committee (DAC), who develops
the guidance based on the report’s findings alongside
any other evidence emerging. These recommendations
are finally confirmed and released by NICE in a separate
document (i.e. the NICE diagnostic guidance, DG). All
NICE guidance and DARs are publicly available at the
NICE home page, from which we identified the report/
guidance pair that were published from the NICE Diag-
nostic Assessment Programme.
Guidance was eligible for inclusion in the study if the
corresponding DAR included a diagnostic question and
a clear diagnostic test accuracy review. Report/guidance
pairs were excluded if they had only reviewed evidence
for monitoring, predictive and/or prognostic questions,
since corresponding studies have designs, features and
labels that differ from those of diagnostic accuracy
studies.
Data extraction
A data extraction form was developed by one reviewer
and piloted independently by two other reviewers on
three reports/guidance documents, which were subse-
quently excluded from the final analysis. From the
remaining 17 report/guidance pairs, five reviewers (ZZ,
HH, JP, CH, MO) independently extracted data from
pre-specified sections in which we expected labels would
be used.
To identify the range of labels used in the reports, we
extracted data from the following DAR sections: ab-
stract, scientific summary, the sections reporting the eli-
gibility criteria and quality assessment process, and the
discussion and conclusion section. From the guidance
document, we extracted data from the following sec-
tions: recommendation, evidence and committee discus-
sion. For the second objective (what labels were used
when studies were weighted differentially), we extracted
data from the DAR sections: scientific summary, eligibil-
ity criteria, discussion and conclusion. In the guidance,
we scrutinized sections on evidence, committee discus-
sion and recommendations for future research. A label
or term was extracted if it referred to any study design
characteristic or feature (specific investigative methods
or strategies used in a study).
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Analysis
We listed all labels, including what proportion of
DAR and guidance documents used labels in each
scrutinized section, and made a descriptive analysis
for the range of labels. Label interpretations were dis-
cussed between authors and then assigned to categor-
ies, based on their level of specificity in describing
DTA studies.
For our second objective, we discussed and included
any instance in which a design feature was ranked or
considered to have a higher (or lower) methodological
preference or status, for the given report or guidance.
For example, in DG17, the use of “within-study com-
parisons” was preferred over other comparisons made
across different groups (Additional file 1: Table S5).
Results
On 6 July 2018, we retrieved all guidelines published
as part of the NICE DAP since its inception. The
programme had at that time released a total of 36
diagnostic reports with guidance, of which 20 (56%)
were found eligible. After exclusion of the three re-
ports used for development and piloting of the data
extraction form, we were able to include a total of 17
(47%) guidelines and their corresponding DARs (Fig. 1)
. The guidelines covered a variety of topics, ranging
from immunochemical tests in colorectal cancer to
devices for measuring exhaled nitric oxide in asthma
and assessment of CT scanners for cardiac imaging
(Additional file 1: Table S1).
Range of labels and study design features
In the 17 report/guidance pairs, we found a total of 53
unique labels (Additional file 1: Table S2). We catego-
rized them as follows, based on their relevance for DTA
studies (Table 1).
One group contained labels considered specific for
DTA-studies (n = 19, 36%). An example is “reference
standard positive studies”, in which only participants
with a positive reference standard test receive the index
test. A second group consisted of umbrella labels, as
these described more global study types but did not pro-
vide specific information of DTA designs (n = 4, 8%). An
example would be “long-term studies”. A third group
were non-specific labels, meaning that they were judged
as more likely referring to other research types (n = 9,
17%). Examples here are “test-treat trials”, in which
management is guided by test results. A fourth group
contained unclear labels: labels for which it was difficult
to decide how they should be interpreted within the
context of DTA studies (n = 3, 6%). An example was a
“(multi-centre) tracker study” (Table 1).
Focusing only on the DTA-specific labels, we could
classify these further into subgroups based on the type
of information they provided. One subgroup was consid-
ered DTA-informative, as these refer to the overall flow
of participants in the study (n = 6, 32%). The distinction
between “single-gate and two-gate studies” falls in this
category. A second subgroup was formed by labels that
were referring to more specific design features. These
could be considered additional DTA-descriptors that do
not refer to an overall design (n = 9, 47%). An example
Fig. 1 Flow diagram of the diagnostic guidance
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Table 1 Labels grouped by DTA-specificity
Label Interpretation Similar/synonym labels
1. DTA-specific labels (n = 19)
1.1 DTA-informative (n = 6)
Comparative performance Comparison of minimum two index test/strategies
[3].
Comparative (diagnostic) accuracy studies
Direct comparisons1 Comparison of two index test/strategies within the
same group/population (i.e. with the same set of
eligibility criteria).
Head to head comparisons; within-study
comparisons
(Prospective cohort) randomized to
either the index test or comparator2
Randomization to either the index test or reference
standard/comparator.
Randomized head-to-head comparisons
(Prospective cohort) receiving the
comparator and at least one index test
with follow up3
All participants receive both an index test and the
reference standard/comparator and are followed up
for a final outcome measure/status.
Reference standard positive studies Only participants with a positive reference standard
test receive the index test.
Single/two-gate diagnostic studies Including one (single set of eligibility criteria) or
two/multiple groups (separate sets of eligibility
criteria) for comparison [9].
Two-study cohorts
1.2 DTA-descriptors (n = 9):
Single/multi-centre study Participants are sampled from a single or from
multiple centres.
Large, multi-centre prospective (UK) study;
two-centre
Primary care study Participants are sampled from settings in the
primary (vs. secondary or tertiary) care.
Consecutive recruitment Participants are sampled consecutively (vs. random
or convenient sampling) [2].
Symptomatic study Including only symptomatic participants.
(Single-gate studies) recruiting populations
at high risk
Including only high risk participants.
Population (-based) studies Including/sampling participants that represent the
target/study population [9].
(Multi-centre) community-based study
Pro- or retrospective studies Data collection (or recruitment) was planned before
(prospective study) the index test and reference
standard were performed or after (retrospective
study) (STARD) [7].
Prospective cohort studies; prospective,
consecutive cohort study; prospective,
international multicentre
Retrospective analysis (of prospective
database)
Post-hoc or non-pre-specified statistical analysis.
Discordant case analysis4 A study that excludes discordant cases in the
analysis.
1.3 General DTA labels (n = 4)
(Diagnostic) cohort studies A diagnostic cohort study in which “individuals are
enrolled before the final outcome (presence or
absence of the target condition) is known” [9] (i.e. a
single cohort/group of suspected participants).
(Retrospective) cohort studies
(Diagnostic) case-control studies/design “(…) studies in which the disease status is already
known before the index test is performed”.
“(…) the reference test is applied only to a
subsample of the participants with or without the
target condition”.
[9]
(Diagnostic) cross-sectional studies Comparison of the result of the index test with that
of the reference standard in the same participant at
the same time.
[9]
(Diagnostic) observational studies A DTA-study that only make use of observational
data e.g. re-interpretation/review of existing tests
results.
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is a “single centre study” or a “symptomatic study”, in
which only symptomatic participants are included. A
third subgroup of DTA-specific labels contains labels
that are very general, typically derived from other study
types, often from etiologic epidemiology studies (n = 4,
21%). An example is “diagnostic cohort studies”.
Only a few labels could be referenced to existing lit-
erature and we had to rely on assumptions for the inter-
pretation of most of the labels (Table 1).
We also explored what study design features were de-
scribed. We identified 4 main design domains and 12 de-
sign features (including descriptors) among the 19 DTA-
specific labels (Additional file 1: Table S3). From the
DTA-specific labels, we also identified a set of labels that
lead to confusion when describing DTA studies. In Add-
itional file 1: Table S4, we list all terms that, in our opin-
ion, should preferably be avoided as other more specific
terms exist.
Table 1 Labels grouped by DTA-specificity (Continued)
Label Interpretation Similar/synonym labels
2. Umbrella terms (n = 4):
Diagnostic accuracy studies A study reporting diagnostic accuracy performance
measures.
(Large prospective cohort) studies
collecting diagnostic accuracy data
End-to-end studies A diagnostic accuracy study that directly links test
results to patient outcomes (such as RCTs) [8].
Long-term studies (following patients for
several years)
A study that includes follow-up of any given out-
come measure/status.
Pilot studies A study that is testing/piloting a setting/feasibility,
often with a small sample size.
3. Non-DTA-specific labels (n = 9)
Test-treat trials A study in which a test guides the treatment
strategy.
Controlled clinical trials A clinical trial including a control (comparator)
group to the intervention group.
Cluster-randomized controlled trial A study that randomizes clusters of participants to
either intervention or control group.
Derivation study A study that focuses on the development of a
prediction model (contra validation of a model).
Observational studies A study that only includes observational data (non-
intervention data).
(Observational) cohort studies A study using data from all cohort-members (in con-
trast to case-control study that uses data from an
outcome-selected subset of the source population)
[5, 10].
Prospective, two cohorts (feasibility,
validation)
A study with two separate cohorts recruited
prospectively.
Randomized controlled trials (RCTs) A study with randomization of participants to either
intervention group(s) or a control (comparator)
group (vs. non-randomized).
(Large multi-centre) RCT
Validation study A study that focuses on validation (of an existing/
developed model).
4. Unclear labels (n = 3)
Diagnostic studies with a control group
(Multi-centre) tracker study
Mixed design (of within-study comparisons)
The table shows the classification of the labels identified and their most likely interpretations. The labels in italic are labels (also) used in the guidance
1Elsewhere, other possible interpretation could be comparison of index test and reference test within the same patient (i.e. fully paired) [11]
2In DTA terminology, the term “comparator” usually refers to one of two index tests (in a comparative study). However, in this case, the “comparator” seems to
refer to other tests that are used for the comparison of the index tests (which is used when a commonly accepted/implemented reference standard is absent)
[12]. Other possible interpretation could be randomization to one of several index tests or randomization to two different test-sequence strategies
3In other contexts of DTA-studies, “follow-up” can imply the clinical follow-up compose the reference standard itself (i.e. the final outcome, diagnosis, is
established by follow-up). This is also referred to as a “delayed type cross-sectional study” [13]. Yet, it can also mean that any given reference standard is
performed at a later time point (delayed) than the index test
4This could also mean studies that identify discordant cases
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Variations in label interpretations
We observed discrepancies in the use and interpretation
of some DTA labels, both among and within reports.
The “single-gate” and “two-gate” labels, for example,
were introduced by Rutjes and colleagues to describe the
use of a single or two sets of eligibility criteria. They did
so as an alternative for the confusing use of “cases” and
“controls” in DTA studies. In the NICE reports, however,
“single-gate” and “two-gate” labels could refer to disease
status (known or unknown), to the study flow (if all pa-
tients or subgroups receive both tests) or to a combin-
ation of these (Table 2).
Frequency of study design labels (between sections)
Overall, labels were most often used in the methods and
results section of the DARs, including the description of
the characteristics of included studies, discussion and
conclusion, and in reporting eligibility criteria. Less fre-
quent was the use of labels in the DAR’s exclusion ta-
bles, quality assessment and summary sections (incl.
scientific summaries, abstract and glossary). Except for
the evidence section, labels were seldom used in the final
guidance of recommendations, committee discussion
and recommendations for future research (Fig. 2).
Labels used to distinguish studies by designs
We also explored if labels had been used to differentiate
studies by design features. This would be the case if a re-
port had given a different weight to different study de-
sign features and had used labels to indicate this
distinction.
From the DARs, we found a total of 7 (41%) reports
that had used labels when differentiating between study
design features. The terminology varied from being clear,
with description such as “Single-gate diagnostic studies
with random or consecutively recruited participants
were considered the optimal design” and “The preferred
data for this review are derived from within-study com-
parisons of intervention and comparator test pathways”,
to less clearly terminology, such as “The majority of
studies which have adjusted for TAB (tissue allocation
bias), have taken a conservative approach by excluding
affected samples, which we consider to be a reasonable
practice” (Additional file 1: Table S5). We found no
guidelines in which the committees had used labels to
emphasize differences between studies.
Discussion
Study design labels can help in the clear and transparent
communication of the way a study was organized. How-
ever, the lack of an agreed upon terminology for DTA
studies acts as a barrier for effective communication.
This lack of clarity may lead to confusion, both in pri-
mary and secondary research.
We investigated the use of study design labels in the
evidence reports (DARs) and final guidance in the NICE
Diagnostic Assessment Programme and were able to
confirm that labels and terms are used very inconsist-
ently. We found that, from a total of 53 unique labels,
approximately one third were specific to DTA-studies.
Yet, these ranged from labels that were informative of
the essential DTA design features, over labels that we
Table 2 Single- and two-gate interpretations
Reference Text Variations in interpretation
Rutjes et al. [9] “(…). All patients pass through a single-gate: a single set of criteria
for study admission, typically defined by the clinical presentation.”
“(…) We refer to this as a “two-gate design using healthy controls”.
Two different sets of inclusion criteria (gates) are used: one for the
diseased and another for the non-diseased participants.”
A single- and two-gate is defined by the number of eligibility
criteria (sets).
DAR8 “The majority of included studies comply with a single-gate design,
a single sample of individuals with unknown metastatic status was
assessed by both the diagnostic test under scrutiny and the refer-
ence standard.”
A single-gate study is defined by a single sample with (un-
known) disease status and all participants receiving both ref-
erence standard and index test.
DAR20 “Single-gate: A study design in which only patients with the target
condition are recruited.”
“(…), single-gate studies, that is, studies in which only patients with
the target condition (suspected sepsis) were recruited.”
A single-gate study is defined by inclusion of only patients by
(known) disease status.
Later, participants with the target condition are described as
suspected individuals.
DAR27 “Single-gate study: Where a single sample of individuals is assessed
by both the index test and reference standard.”
“Two-gate study: Studies which employ separate sampling schemes
for diseased and non-diseased participants, with both groups being
assessed by the index test.”
A single-gate is defined by both (a single set of) eligibility cri-
teria and study flow (receiving both tests).
Two-gate study is defined by (two sets of) eligibility criteria,
(known) disease status and study flow both groups receiving
the index test.
DG33 “Single-gate study: Study design where participants’ disease status is
unknown and the index test result is evaluated against the
reference standard to confirm the diagnosis”
A single-gate is defined by inclusion of participants by only
(unknown) disease status and receiving both tests.
The table shows variations in the interpretations of the single- and two-gate labels from included DG. The first row shows the citations from the original definition
made by Rutjes et al. [9]
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classified as descriptors, to labels that were general,
mostly adopted from other study types, and with an am-
biguous meaning within the context of DTA study
designs.
Our study has several limitations and uncertainties.
We did not perform additional verification of the data
extraction. However, we believe that a label is a relatively
easily identifiable item to extract and the risk of having
missed labels is low. It was not always clear if the labels
belonged to the overall clinical effectiveness review or
specifically to the DTA review. Some of the labels we ex-
tracted may not exclusively be intended to describe the
DTA studies. We also relied on a rather broad definition
of study design labels, which may be sensitive to individ-
ual interpretation. As we focused on the variation of la-
bels and not on the frequencies of each label, we do not
consider this to have affected the results.
Among the DTA-informative labels, we found ambigu-
ity, as it was not always clear for us how to interpret the
various labels. In particular, two (related) terms were un-
clear. The term “comparator” has previously been de-
fined as referring to a second or third index test in a
comparative accuracy study, in which all index tests are
evaluated against a single reference standard [3, 11].
However, in the scenario where there is no agreed upon
clinical reference standard, this imperfect reference
standard is sometimes also referred to as “comparator”.
A second source of confusion was the use of the term
“randomization”. This lack of clarity in the distinction
between the index test(s), comparator and reference
standard makes it difficult to understand what arms par-
ticipants had been allocated to.
We also observed variation in the use of “single-gate”
and “two-gate” designs, although this label is unique to
DTA studies. Some reports defined the terms by inclu-
sion of a single or multiple groups/sets of eligibility,
while in others they were defined by disease status
(known or unknown) and/or who received both tests.
The second group of descriptors referred to features
that are easier to interpret, such as “single centre” or
“multicentre studies”. One set of terms was ambiguous:
the use of “prospective” and “retrospective” as descriptors
of studies. These could refer to one of several different
components: recruitment, data collection and analysis. In
some cases, it was clear from the context what authors
were referring to, as in “prospective cohort randomized to
either the index test or comparator”, “retrospective ana-
lysis”. In other cases, the interpretation was less clear.
To our knowledge, no other form of DTA guidance
provides more standardized labels of study designs.
Neither the US AHRQ Methods Guide for Medical
Tests Reviews or the Cochrane Handbook for DTA
Reviews provides standardized terms [8, 14]. Hence,
the lack of consistent and standardized DTA-
terminology may play a key role in this use of am-
biguous labels. For example, terms that have been
used in epidemiology to describe the timing of re-
cruitment and data collection are not always straight-
forward when applied in DTA studies. This includes
terms as case-control study, longitudinal study or his-
torical cohort study. One difficulty lies in the fact
that DTA studies are essentially cross-sectional. The
use of “borrowed” labels makes any interpretation of
the exact DTA design difficult. For this reason, we
believe that the use of such terms as “retro-”and
“prospective”, “longitudinal”, “cohort” and “case-con-
trol” should be avoided and that more specific alter-
natives are needed for describing DTA designs.
Only 7 reports had used labels when they differenti-
ated between studies, while no guidance document had.
This shows that the use of labels in communicating im-
portant differences is limited, which consequently makes
Fig. 2 Frequency of labels used in DARs and guidance
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interpretation difficult. Committees are often assembled
from experts who will read the reports in detail. Yet,
without standardized design terminology for clear com-
munication in general, the attention to different degrees
of validity in DTA studies in the overall assessment may
be hindered.
Conclusion
Taken together, our results show that there is a lack of
standardized terms and labels to characterize differences
in DTA-study design. This presents a barrier to inform-
ative reporting of primary studies and hinders attempts
at making valid synthesis of the available evidence
which, in turn, may have consequences for developing
evidence-based guidelines and other recommendations
for policy makers. Although attempts to standardize lan-
guage are notoriously difficult, the research community
should consider investing more efforts in developing and
consistently using descriptive labels, to avoid confusion
and misinterpretation.
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